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Abstract
Mutations in, or elevated dosage of, SNCA, the gene for a-synuclein (a-syn), cause familial Parkinson’s disease (PD). Mouse
lines overexpressing the mutant human A53Ta-syn may represent a model of early PD. They display progressive motor
deficits, abnormal cellular accumulation of a-syn, and deficits in dopamine-dependent corticostriatal plasticity, which, in the
absence of overt nigrostriatal degeneration, suggest there are age-related deficits in striatal dopamine (DA) signalling. In
addition A53Ta-syn overexpression in cultured rodent neurons has been reported to inhibit transmitter release. Therefore
here we have characterized for the first time DA release in the striatum of mice overexpressing human A53Ta-syn, and
explored whether A53Ta-syn overexpression causes deficits in the release of DA. We used fast-scan cyclic voltammetry to
detect DA release at carbon-fibre microelectrodes in acute striatal slices from two different lines of A53Ta-syn-
overexpressing mice, at up to 24 months. In A53Ta-syn overexpressors, mean DA release evoked by a single stimulus pulse
was not different from wild-types, in either dorsal striatum or nucleus accumbens. However the frequency responsiveness of
DA release was slightly modified in A53Ta-syn overexpressors, and in particular showed slight deficiency when the
confounding effects of striatal ACh acting at presynaptic nicotinic receptors (nAChRs) were antagonized. The re-release of
DA was unmodified after single-pulse stimuli, but after prolonged stimulation trains, A53Ta-syn overexpressors showed
enhanced recovery of DA release at old age, in keeping with elevated striatal DA content. In summary, A53Ta-syn
overexpression in mice causes subtle changes in the regulation of DA release in the striatum. While modest, these
modifications may indicate or contribute to striatal dysfunction.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by the degeneration of nigrostriatal dopamine
(DA) neurons, and the presence of proteinaceous aggregates,
called Lewy bodies, in surviving DA neurons. A major component
of Lewy bodies is a small protein called alpha synuclein (a-syn) [1].
Mutations in [2,3], or elevated dosage of [4], SNCA, the gene
coding for a-syn, including the A53T mutation [2], cause rare
familial forms of PD in humans. Recent GWAS studies have also
shown a strong association between single nucleotide polymor-
phisms (SNPs) in the SNCA locus and idiopathic PD [5,6].
Therefore a-syn is strongly implicated in the pathogenesis of PD.
The protein a-syn is expressed presynaptically throughout the
central nervous system but, despite extensive investigation [7–11],
its exact functions remain incompletely resolved. Recent work has
focused on its presynaptic roles in controlling vesicle fusion
[11,12], vesicle pool regulation [13–15] and vesicle clustering [16].
In cultured cells, overexpression of wild-type or mutant a-syn has
been reported to cause deficits in vesicle cycling and transmitter
release [11,16]. However, the effect of mutant a-syn on
dopaminergic signalling within the striatum, in regions differen-
tially vulnerable to degeneration in PD, and in response to
stimulation across the range of frequencies seen in vivo, remains
unexplored.
Overexpression of different mutant SNCA has been used to
generate several animal models of PD [17,18]. Mouse lines
overexpressing human A53Ta-syn under control of the mouse
prion (PrP) promoter [19–22] constitute one such model. In these
mice, the human a-syn transgene is expressed in neurons that
include nigral neurons, and in striatal synapses, but not in striatal
neurons [19]. These mice show pathological changes including
abnormal subcellular localisation of a-syn in many brain regions,
mild accumulation of insoluble a-syn in the substantia nigra and
non-specific signs of neurodegeneration in the olfactory bulb, in
the absence of overt nigrostriatal degeneration. They also show
age-related motor deficits including reduced rearing, step length
and rotarod performance. Furthermore, these mice show progres-
sive presynaptic changes, including the upregulation of vesicle-
associated proteins such as the chaperone 14-3-3 [21], and
progressive striatal postsynaptic changes, including increased DA
receptor expression, altered expression of proteins downstream of
DA signalling and reduced corticostriatal long term depression
[20,22]. These changes are suggestive of progressive deficits in
striatal DA signalling. Therefore these mice may model early PD-
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36397associated changes and hence are useful for investigating early
pathological mechanisms.
Mutant a-syn has been shown to reduce transmitter release in
cultured neurons [11,16], and since A53Ta-syn overexpressing
mice show changes suggestive of disrupted striatal DA transmis-
sion, we have directly investigated whether A53Ta-syn overex-
pression in mice causes deficits in dynamic striatal DA release. We
have explored DA release in two independent lines of human
A53Ta-syn overexpressing mice (lines A and B) compared to wild-
type (WT) animals for two age ranges, 6–14 months and 18–24
months. We used fast-scan cyclic voltammetry (FCV) at carbon-
fibre microelectrodes to detect DA release in real time, in acute
striatal slices, in two striatal regions differentially affected in PD
(caudate-putamen (CPu) and nucleus accumbens (NAc)).
Methods
Animals
Female mice overexpressing human A53Ta-syn under control
of the mouse prion promoter, described previously [19,20], were
compared to wild-type mice (WT) of the same background strain,
FVB/N. These A53Ta-syn overexpressing mice show an approx-
imately 1.5 fold level of a-syn protein in the striatum, and high
levels of a-syn expression in midbrain DA neuons [19,20]. Mice
from two different founder lines (line A and line B) were used, to
control for effects due to random gene insertion. Mice were used at
2 ages, a mid-adult age (6–14 months), before the onset of motor
impairments, and an old age (18–24 months) at which the onset of
motor impairments has been reported [19]. All procedures were
carried out in accordance with UK Home Office project licence
and local guidelines.
Slice preparation
Striatal slices were prepared as described previously [23,24]. In
brief, mice were sacrificed by cervical dislocation and the brains
removed and transferred to ice-cold HEPES-based buffer
containing in mM: 120 NaCl, 20 NaHCO3, 6.7 HEPES acid, 5
KCl, 3.3 HEPES salt, 2 CaCl2, 2 MgSO4, 1.2 KH2PO4,1 0
glucose, saturated with 95%O2/5%CO2. Acute 300 mm thick
coronal striatal slices, containing both dorsal striatum (CPu) and
nucleus accumbens core (NAc) were prepared in ice-cold HEPES-
based buffer and cut using a vibratome (VT1000S or VT1200S;
Leica). Slices were kept at room temperature in HEPES-based
buffer for 1 hour. Slices were transferred to the recording chamber
and superfused at approximately 1.5 ml/min in bicarbonate
buffer-based artificial CSF (aCSF) containing in mM: 124 NaCl,
26 NaHCO3, 3.8 KCl, 2.4 CaCl2, 1.3 MgSO4, 1.3 KH2PO4,1 0
glucose, saturated with 95%O2/5%CO2, at 31–33uC. Slices were
allowed to equilibrate for 30 minutes prior to recording.
Electrical stimulation
DA release was evoked using a surface bipolar concentric Pt/Ir
electode (25 mm diameter, FHC) as described previously [23,24].
The stimulating electrode was placed locally, approximately
100 mm from the recording electrode. Stimulation pulses of
200 ms duration were applied at 0.6 mA, a perimaximal current
(the minimum current found to evoke maximum DA release with a
single 200 ms pulse).
Voltammetry
Evoked extracellular DA concentration ([DA]o) was measured
using FCV at carbon-fibre microelectrodes (diameter 7–10 mm, tip
length 50–120 mm). A triangular voltage waveform was scanned
across the microelectrode (2700 to +1300 mV and back vs Ag/
AgCl reference, scan rate 800 V/s) using a Millar voltammeter,
with a sampling frequency of 8 Hz, as described previously [24].
Evoked currents were confirmed as DA by comparison of the
voltammogram with that produced during calibration with applied
DA in aCSF (oxidation peak +500–600 mV and reduction peak
2200 mV). Currents at the oxidation peak potential were
measured from the baseline of each voltammogram and plotted
against time to provide profiles of [DA]o versus time. Electrodes
were calibrated in 2 mM DA in aCSF. Calibration solutions were
made immediately before use from stock solution of 2.5 mM DA
in 0.1 M HClO4 stored at 4uC.
Experimental Design and Data Analysis
Unless otherwise stated, repeated electrical stimuli were applied
at 2.5 min intervals, by when release was reproducible and
sustainable for several hours. [DA]o varies between different
striatal sampling sites [25]. To obtain representative measure-
ments of DA release, [DA]o was measured at 5 sites in CPu
(dorsolateral, dorsomedial, ventrolateral, ventromedial and cen-
tral) and 2 sites in NAc (lateral and medial), in each animal. Data
was averaged within CPu and NAc, across animals. In each site, 2
single stimulus pulses, separated by 4 s were applied. [DA]o
evoked by the initial pulse was used as a measure of DA release,
from a naive site. [DA]o evoked by the second pulse was used as a
measure of DA re-release following a single stimulus. In
experiments investigating frequency response, data sets were
obtained from single sites per animal, in dorsolateral CPu. Stimuli
consisted of 4 pulses at a range of frequencies (5–100 Hz), covering
the full range of DA neuron firing reported in vivo [26,27]. Stimuli
were given in a pseudorandomized order and in triplicate. In
experiments investigating recovery of release following prolonged
stimulation a single site per slice, in dorsolateral CPu, was used. A
prolonged stimulation (10 Hz, 60 s) was applied and recovery of
release monitored by a single stimulus pulse at 10, 30, 60, 120, 270
and subsequent 150 s intervals after the end of prolonged
stimulation.
Data were acquired and analysed using Axoscope 10.2
(Molecular Devices) or Strathclyde Whole Cell Program (Univer-
sity of Strathclyde, Glasgow, UK) and locally written programs.
Data are expressed as mean 6 SEM with n=number of
observations. The number of animals contributing to each data
set was 3–8. To compare DA uptake in CPu, the falling phases of
all DA profiles with a peak [DA]o over 1.5 mM were time-locked to
the timepoint when [DA]o fell below 1.5 mM, averaged and
compared between genotypes. This concentration of [DA]o was
selected to allow comparison of uptake at a concentration where
signal to noise ratio is large, whilst still including a large number of
data points. For experiments investigating frequency response,
peak [DA]o evoked by 4 pulses (5–100 Hz) was normalised to peak
[DA]o evoked by a single pulse in the same drug condition. In
experiments investigating DA re-release following single pulse
stimulation, peak [DA]o evoked by a second pulse was normalised
to peak [DA]o evoked by the initial stimulation. In experiments
investigating recovery of DA release following prolonged stimu-
lation, data was normalised in two ways. To investigate the extent
of recovery of release, data was normalised to peak [DA]o evoked
by the initial prolonged stimulation. To investigate the rate of
recovery, data was normalised to the maximum recovery
(calculated as the mean peak [DA]o evoked by single pulse
stimulations 35–42 mins following prolonged stimulation).
Comparisons for differences in means were carried out in
GraphPad Prism using One or Two-way ANOVAs and post hoc
Bonferroni’s t tests. Curve fits were carried out in GraphPad Prism
using nonlinear regression analysis, using sigmoidal dose-response
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considered as P,0.05.
Drugs
D-AP5, Bicuculline methiodide, Dihydro-b-erythroidine
(DHbE), 4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-
yl)-benzenamine hydrochloride (GYKI 52466 hydrochloride), L-
714,626, (S)-a-methyl-4-carboxyphenylglycine (MCPG) and sa-
clofen were purchased from Tocris Biosciences or Ascent
Scientific. Drugs were dissolved in distilled water or aqueous
alkali ((S)-MCPG), aqueous acid (GYKI 52466 hydrochloride) or
dimethylsulphoxide (DMSO) (L-741,626) to make stock aliquots
1000–100006 final concentrations and stored at 220uC. Final
concentrations were made up in aCSF immediately before use.
Results
Single pulse-evoked dopamine release is not different in
A53Ta-syn overexpressers
FCV in acute striatal slices was used to investigate DA release in
2 lines of A53Ta-syn overexpressing mice (lines A and B) versus
WT mice, at 2 ages, 6–14 months and 18–24 months. We first
explored [DA]o evoked by a single electrical stimulus pulse in each
of two striatal regions, the caudate-putamen (CPu) and nucleus
accumbens core (NAc). These regions are differentially affected in
PD and DA release may be differentially controlled by synucleins
in these regions [28]. Consistent with previous studies [25], [DA]o
was lower in NAc than in CPu in all genotypes (Fig. 1a,b).
However there was no significant difference between genotypes in
mean peak [DA]o evoked by a single pulse, at either age, in either
CPu (n=15–40), or NAc (n=6–14)( Fig. 1a,b). Data was
additionally analysed by sub-region within CPu, and by appro-
priate groups of sub-regions (dorsal versus ventral, and medial
versus lateral). There was no significant effect of genotype in any
sub-region (n=3–8), or any group of subregion (n=6–16), at either
age. Therefore data were grouped into a single CPu population for
further analysis. There was also no significant difference in mean
peak [DA]o evoked by a single pulse between 6–14 month versus
18–24 month mice for any genotype, in either region (n=6–40)
(Fig. 1a,b). Cumulative distribution plots of evoked [DA]o
indicated broadly similar spreads of data in all genotypes, with
the exception of in CPu in 18–24 month mice where distribution
was significantly different between genotypes and the cumulative
distribution plot showed a slightly decreased slope in A53Ta-syn
overexpressors (Fig. 1c). The slopes of falling phases of DA
transients are a function of DA uptake rate [29], and were
compared between genotypes at a [DA]o of 1.5 mM. There was no
significant interaction between genotype and time after [DA]o
falling below 1.5 mM( n=9–28) (Fig. 1d).
A53Ta-syn overexpression modifies the frequency
dependence of DA release
DA neurons fire at a range of frequencies in vivo, from tonic, low
frequency, firing, at ,2–5 Hz, to bursts of high frequency firing, at
,15–40 Hz or higher [26,27]. These firing patterns have different
behavioural significance [30]. The filtering of these firing patterns
by DA neuron terminals into DA release can be highly dynamic
[24,25,31]. We investigated whether overexpression of A53Ta-syn
differentially modified DA release in response to stimulations of
different frequencies across this physiological range (4 pulses, 5–
100 Hz). This was explored in dorsolateral CPu only.
The frequency response of peak [DA]o formed a characteristic
inverted U shape [24,32] in all genotypes, at both ages (Fig. 2a,b
upper). This response is due to a number of activity-dependent
processes acting on [DA]o, including strong short term depression
of release [25], the activation of D2 autoreceptors at low
frequencies [33,34] and the frequency-dependent summation of
DA release and uptake. At 6–14 months there was no significant
difference in the frequency response between genotypes (normal-
ised to peak [DA]o evoked by a single pulse) (n=9–15)(Fig. 2b
upper left). At 18–24 months, normalised peak [DA]o evoked by
an intermediate frequency (10 Hz) was slightly increased in line B
compared to WT (2-way ANOVA, post hoc Bonferroni t test,
P,0.01; n=9–15), but not in line A (Fig. 2b upper right).
The frequency dependence of striatal DA release is strongly
controlled by acetylcholine (ACh) [31,35]. ACh is released from
striatal cholinergic interneurons and acts at nicotinic acetylcholine
receptors (nAChRs) on DA axons. When nAChRs are active,
initial DA release probability in response to a given depolarising
stimulus is relatively high [31,36]. DA release then shows strong
short term depression so, as shown above, release is relatively
insensitive to firing frequency. When nAChRs are inhibited, initial
DA release probability is reduced. This reduction relieves
depression during a train and release becomes strongly dependent
on stimulation frequency [31,35]. In vivo, striatal cholinergic
interneurons show dynamic changes in activity, ranging from
pauses to brief bursts that might co-vary with activity in DA
neurons [37–39] but the state of nAChR activation is not known.
In any event, nAChR activity will mask, or confound, the
regulation of DA release by presynaptic mechanisms that are
intrinsic to the DA axon. Therefore we also investigated whether
overexpression of A53Ta-syn modifies DA release when nAChRs
are inhibited, using the nAChR antagonist DHbE( 1mM).
With DHbE, [DA]o evoked by 4 pulses, showed a strong
frequency sensitivity, increasing with increasing frequency
(Fig. 2a,b lower), as previously reported [31,35]. This frequency
response was seen in all genotypes across ages. However, at 6–14
months, peak [DA]o evoked by 100 Hz stimulation (normalised to
[DA]o evoked by a single pulse) was lower in line B compared to
WT (2-way ANOVA, post hoc Bonferroni t test, P,0.001; n=9–
15). There was no significant difference between line A and WT
(Fig. 2b lower left). In contrast at 18–24 months, peak [DA]o
evoked by 100 Hz stimulation (normalised to [DA]o evoked by a
single pulse) was lower in both lines A and B compared to WT (2-
way ANOVA, post hoc Bonferroni t test, P,0.05; n=9–15)(Fig. 2b
lower right).
A53Ta-syn overexpression effects on re-release
We explored the effect of A53Ta-syn overexpression on the
recovery of DA re-release evoked by single pulses in two
paradigms, either following a single stimulus pulse or following a
prolonged stimulus train. In the first protocol, re-release was
explored at second pulse given at an inter-stimulus interval of 4 s,
a timepoint when deletion of a-synuclein has been reported to
modify DA re-release in some studies [40], although not others
[41]. The ratio of peak [DA]o evoked by this second compared to
the first pulse was ,0.3, in all genotypes at both ages (Fig. 3). This
is characteristic of the strong short term depression of DA release
seen in vitro, from which DA release takes 30–60 s to recover
[25,40]. There was however, no significant difference between
genotypes in the P2/P1 ratio, for either age range, in CPu (Fig. 3,
n=15–40) or NAc (data not shown).
It has been reported that a-syn may control recycling or
reclustering of vesicle pools after more prolonged stimulation
[15,16]. Thus in the second protocol to explore re-release, we
explored recovery of release after prolonged stimulation trains
(60 s at 10 Hz) after which DA release is undetectable for several
seconds before partial recovery. These experiments focussed on
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36397Figure 1. A53Ta-syn overexpression does not affect [DA]o evoked by a single stimulus pulse. (a) Profiles of mean [DA]o6 SEM versus
time, after single pulse stimulation (arrow). There was no significant difference in [DA]o between genotypes, at either age or in either region (n=15–
40 (CPu), n=6–14 (NAc)). There was also no significant difference in mean peak [DA]o between 6–14 and 18–24 month mice of any genotype (n=15–
40 (CPu), n=6–14 (NAc)). (b) Mean peak [DA]o6 SEM evoked by a single pulse. (c) Cumulative distribution plots of peak [DA]o (mM) evoked by a single
stimulation pulse. Curve fits are sigmoidal variable slope curves, R
2.0.93. Curves are not significantly different between genotypes at 6–14 months in
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were carried out in the presence of a mixture of antagonists for
glutamate (NMDA: D-APV, 50 mM, mGluR: (S)-MCPG,
200 mM, AMPA: GYKI52466, 10 mM), GABA (GABAA: bicu-
culline, 10 mM, GABAB: saclofen, 50 mM) and D2 (L-714,626,
1 mM) receptors which may modulate DA release during long
stimulation trains (but not significantly during sub-second stimu-
lations [25,42]). A prolonged 10 Hz stimulus train (60 s) was
applied and DA re-release was monitored using a single stimulus
pulse at timepoints 10, 30, 60, 120, 270 s and at subsequent 150 s
intervals after the end of the 10 Hz train. There was no significant
difference between genotypes in the mean peak [DA]o evoked by
the initial long 10 Hz stimulus train (Fig. 4a) but, recovery of
single pulse [DA]o varied with genotypes when normalised to
either the peak [DA]o evoked by the initial stimulus (Fig. 4b)o rt o
the maximum recovery of [DA]o (Fig. 4c). DA release by a single
pulse recovered to ,25–35% of release evoked by the initial
prolonged stimulation, but to a significantly greater extent
(Fig. 4b) and with a significantly enhanced rate (Fig. 4c) in both
A53Ta-syn overexpressing lines compared to WT. Two-phase




Mice that overexpress A53T-SNCA may be a useful model to
explore the processes underlying PD since they have abnormalities
in striatal presynaptic protein expression and postsynaptic
signalling, and have cellular aggregations and motor behaviours
CPu or at either age in NAc, but are significantly different in CPu at 18–24 months. (d) Mean decay phases of concentration-matched DA transients in
CPu do not differ between genotypes (n=9–28).
doi:10.1371/journal.pone.0036397.g001
Figure 2. A53Ta-syn overexpression causes subtle deficits in DA release in response to high versus low frequency stimulation,
when nAChRs are inhibited. (a) Profiles of mean [DA]o6 SEM versus time, evoked by 4-pulse stimulation (1–100 Hz), with intact nAChR activity
(upper), and with nAChR inhibition (DHbE, 1 mM) (lower)(6–14 months only shown). (b) Mean peak [DA]o6SEM evoked by 4-pulse stimulation (1–
100 Hz), normalised to single pulse release, with nAChR activity (upper) and with nAChR inhibition (in DHbE, 1 mM)(lower). With intact nAChR activity,
there was no significant difference in frequency response between genotypes at 6–14 months (n=9–15). At 18–24 months, normalised peak [DA]o
evoked by 10 Hz stimulation was slightly greater in line B versus WT (2-way ANOVA, post hoc Bonferroni t tests, p,0.05; n=9–15). With nAChR
inhibition, in DHbE, at 6–14 months, normalised peak [DA]o evoked by 100 Hz stimulation was significantly lower in line B than WT (2-way ANOVA,
post hoc Bonferroni t test, p,0.001; n=9–15) and, at 18–24 months, normalised peak [DA]o evoked by 100 Hz stimulation was significantly lower in
both A53Ta-syn overexpressing lines compared to WT (2-way ANOVA, post hoc Bonferroni t test, p,0.05; n=9–15).
doi:10.1371/journal.pone.0036397.g002
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21]. Somewhat paradoxically, these mice have also been reported
to have elevated striatal DA content [20]. DA releasability in this
model has however previously remained unknown. Here, we
explored directly the properties of DA release in the striatum of
these mice using subsecond detection at extracellular carbon
microelectrodes. We show that normal extracellular concentra-
tions of DA can be evoked in these mice, but that A53Ta-syn
overexpression causes subtle modifications to some properties of
release. In particular, A53Ta-syn overexpressors showed a deficit
in the frequency responsiveness of DA release, when the
confounding effects of striatal ACh acting at presynaptic nAChRs
were antagonized, and a slight increase in the recovery of DA
release following prolonged stimulation, in old-aged mice. These
changes in regulation of release are modest but may contribute to
or indicate striatal dysfunction.
Absolute [DA]o is not modified
a-synuclein has been reported to be a negative regulator of
transmitter release, in both dopaminergic and non-dopaminergic
systems [11,16,28,40,41] and knockout of the synuclein family
results in elevated [DA]o evoked by single pulses in dorsal striatum,
but not in the adjacent NAc [28]. We investigated whether
conversely, overexpression of A53Ta-syn reduced single pulse-
evoked DA release in CPu or NAc, but A53Ta-syn overexpression
had no significant effect on mean peak DA release evoked by
single stimuli, in either striatal region, in either mid-age (6–14
months) or old-age (18–24 months) mice. Analysis of the
cumulative distribution of individual data points did indicate
slight changes in DA releasability in a subset of sites in CPu, due
either to a relative reduction in low releasing sites or increase in
high-releasing sites, but overall, [DA]o evoked in A53T over-
expressors were typical of those seen in wild-types. However, these
data, alongside the finding that A53Ta-syn overexpressors have a
20–30% increase in striatal DA content, indicate that there is a
decrease in the fraction of stored DA that is released by each
Figure 3. DA re-release following a single pulse stimulation is unchanged in A53Ta-syn overexpressors. (a) Profiles of mean [DA]o6
SEM versus time, evoked by 2 single pulse stimulations, separated by 4 s. There was no significant difference in normalised [DA]o evoked by a second
pulse between genotypes, at either age, in either region (CPu only shown)(n=15–40). (b) Mean peak [DA]o6SEM evoked by second stimulus pulse,
normalised to peak [DA]o evoked by first stimulus pulse.
doi:10.1371/journal.pone.0036397.g003
Figure 4. A53Ta-syn overexpressors show enhanced recovery of DA release following prolonged stimulation. (a) Mean peak [DA]o6
SEM evoked during a prolonged 10 Hz train (60 s), normalised to mean peak [DA]o evoked by a single pulse. There was no significant difference in
normalised peak [DA]o between genotypes (n=8–10). (b,c) Mean peak [DA]o6 SEM evoked by a single stimulus pulse, against time after the end of
initial prolonged stimulation. Values were normalised to (b) peak [DA]o evoked by initial 10 Hz train or to (c) maximum [DA]o evoked by subsequent
single pulses. Curve fits are two phase exponential associations, R
2.0.80. Both sets of curves are significantly different between genotypes. Inset is
the expanded initial 5 minutes following the end of prolonged stimulation, showing the same curve fits as main graphs.
doi:10.1371/journal.pone.0036397.g004
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releasability.
Frequency response of DA release is subtly modified
DA neurons fire at a range of frequencies in vivo, [26,27] and
DA release can be differently regulated or filtered during these
different frequencies of activity [31,35]. This filtering is strongly
dependent on striatal network factors, including ACh released
from striatal cholinergic interneurons, which acts at nAChRs on
DA axons to dynamically modulate DA release [31,35,36]. Thus it
was important here to assess [DA]o evoked by a full range of
physiologically relevant firing frequencies with and without
activation of nAChRs. In drug-free conditions, when nAChRs
can be activated by endogenous striatal ACh, the frequency
response of DA release followed a characteristic inverted-U
relationship in all genotypes [23]. The frequency response of DA
release was broadly similar across genotypes but was subtly altered
at intermediate frequencies in old-aged mice in one line of A53Ta-
syn overexpressors, line B. This outcome is difficult to interpret
since it was not common to both lines of A53T overexpressors, but
may reflect a more pronounced phenotype in this line as evidenced
by a higher degree of overexpression and earlier deficits in
spontaneous locomotion in this line (see [19]).
When the confounding effects of nAChRs were removed,
through addition of an nAChR antagonist, the underlying
frequency sensitivity of DA release was enhanced in each genotype
(as published previously in wild types [31,35,36]), but notably the
overall frequency sensitivity of evoked [DA]o was significantly less
in A53Ta-syn overexpressors compared to wild-type, in one
A53Ta-syn line of mid-aged mice (line B) and in both lines of old-
aged mice. Reduced frequency sensitivity can arise through a
number of mechanisms. In many neuronal systems, frequency
sensitivity and initial transmitter release probability are inversely
correlated [43,44], since an increased release probability leads to
increased short-term depression of release, and hence a decrease in
subsequent transmitter release. Therefore reduced frequency
sensitivity of DA release may result from an increase in initial
release probability [25,45]. Alternatively it may arise from a
reduction in short-term facilitatory processes that underlie short-
term plasticity in neurotransmitter release. Through either possible
underlying mechanism, the dynamic increases in extracellular DA
concentrations that are thought to signal bursts in DA neuron
firing to postsynaptic neurons, may be compromised by this deficit,
and in turn contribute to the progressive postsynaptic changes,
such as increased DA receptor expression, and motor deficits that
occur in these mice.
Modified DA synapse function is indicated by changes to
DA re-release
a-syn has been implicated in the control of transmitter vesicle
pools, their trafficking, reclustering and re-release [13–16,40]. In
addition A53Ta-syn overexpressors show upregulation of several
proteins associated with vesicle trafficking and cycling, such as the
chaperone protein 14-3-3 and endocytic protein dynamin [21].
We used two different protocols differing in stimulation intensity,
to explore whether A53T overexpression modified DA re-release
in CPu. Release in a mild paired-pulse paradigm was not different
between genotypes but following a prolonged stimulus train that
was designed to deplete DA terminals of readily releasable vesicles
[46], overexpression of A53Ta-syn altered the recovery of DA
release in old-aged animals. The extent and rate of recovery of
release was significantly greater in both lines of A53Ta-syn
overexpressors compared to WT. These data are in keeping with
the enhanced DA storage capability of these animals [20], but may
also indicate an enhanced vesicle reserve pool which can more
readily replace the normally releasable pool; indeed hippocampal
neurons from a-syn knockout mice are reported conversely to have
a decrease in the size of glutamate reserve pools [14]. Alternatively
this enhanced DA re-releasability may result from the upregula-
tion of vesicle chaperone proteins seen in these mice [21]. Then
again, the increase in re-release could be caused by an
upregulation of any number of mechanisms that contribute to
DA availability (e.g. synthesis), and could thus be in keeping with
compensatory presynaptic adaptations that have occurred in vivo
after A53T expression to offset deficits in DA releasability e.g.
those resulting from reduced fractional DA release or deficits in
high frequency release. These data are however inconsistent with
findings in cultured neurons that a-syn overexpression decreases
vesicle reclustering, and hence transmitter release, following
prolonged stimulation [16]. Surprisingly little is established
regarding the factors that regulate the availability and releasability
of vesicular pools for DA, and DA vesicles do not readily cluster
anatomically at presynaptic active zones [28] unlike at synapses for
many other transmitters e.g. glutamate [47], suggesting that
different factors may regulate vesicular pools for DA compared to
glutamate.
Conclusions
Here we show that A53Ta-syn overexpressing mice have subtle
modifications to striatal DA release. They have small but
significant deficits in the sensitivity of DA release to frequency of
activity, and they have enhanced recovery of DA re-release
following prolonged stimulation. These DA synapse dysfunctions
are modest but may nonetheless contribute to postsynaptic
changes and motor deficits.
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